Clinical Practice Guidelines in Breast Cancer by Chinese Anti-Cancer Association(2015 version): interpretation of updates in terms of systemic treatment

doi:10.3877/cma.j.issn.1674-0807.2016.02.001

Abstract

Abstract:

In order to standardize the management of breast cancer, Chinese Anti-Cancer Association(CACA) issued the first edition of Clinical Practice Guidelines in Breast Cancer in 2007 and updates it every other year based on latest evidences. The newly published CACA Clinical Practice Guidelines in Breast Cancer in 2015 covers the overall management of breast cancer including screening, imaging, pathology, surgery and systemic treatment. This article mainly focused on the updates of systemic treatment for breast cancer patients in 2015 version, with regard to endocrine therapy, anti-HER-2 molecular targeted therapy, chemotherapy and bone protection.

Key words: Breast neoplasms, Drug therapy, Practice guideline

Biyun Wang, Chengcheng Gong, Xichun Hu. Clinical Practice Guidelines in Breast Cancer by Chinese Anti-Cancer Association(2015 version): interpretation of updates in terms of systemic treatment[J]. Chinese Journal of Breast Disease(Electronic Edition), 2016, 10(02): 65-70.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2016.02.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2016/V10/I02/65

References 58

[1]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2007 版)[J]. 中国癌症杂志,2007,17(5):410-428.
[2]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015 版)[J]. 中国癌症杂志,2015,25(9):692-754.
[3]	Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J]. Lancet,2013,381(9869):805-816.
[4]	Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6935 women with early breast cancer [EB/OL]. [2016-02-03].http:/ /meetinglibrary.asco.org/content/112995-132.
[5]	LHRH-agonists in Early Breast Cancer Overview group, Cuzick J,Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials[J]. Lancet, 2007, 369(9574):1711-1723.
[6]	Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:62-month follow-up from the ABCSG-12 randomised trial[J].Lancet Oncol,2011,12(7):631-641.
[7]	Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med,2014,371(2):107-118.
[8]	Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J].N Engl J Med,2012,366(6):520-529.
[9]	Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study[J]. J Clin Oncol,2009,27(27):4530-4535.
[10]	Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant,formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment[J]. J Clin Oncol,2002,20(16):3396-3403.
[11]	Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy:results of a North American trial[J]. J Clin Oncol,2002,20(16):3386-3395.
[12]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2013 版)[J]. 中国癌症杂志,2013,23(8):637-693.
[13]	Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲtrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30):4594-4600.
[14]	Jiang ZF, Zhang QY, Shao ZM, et al. A phase Ⅲstudy of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the 500 mg dose [EB/OL]. [2016-02-01]. http:/ /m.cancerres.aacrjournals.org/content/75/9_Supplement/P1-13-07.short.
[15]	Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med,2015,372(10):923-932.
[16]	Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31):3997-4013.
[17]	《乳腺癌HER2 检测指南(2014 版)》编写组. 乳腺癌HER2 检测指南(2014 版)[J]. 中华病理学杂志,2014,43(4):262-267.
[18]	Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med,2001,344(11):783-792.
[19]	Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱtrial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol,2005,23(19):4265-4274.
[20]	Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2):109-119.
[21]	Swain S,Kim SB,Cortes J,et al. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz),trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)[EB/OL]. [2016-02-01].https:/ /www. esmo. org/Conferences/Past-Conferences/ESMO-2014-Congress/News-Articles/Final-Overall-Survival-Analysis-from-the-CLEOPATRA-Study-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer.
[22]	Swain SM, Ewer MS, Cortes J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized,double-blind, placebo-controlled phase Ⅲ study [J]. Oncologist,2013,18(3):257-264.
[23]	Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2016,14(3):324-354.
[24]	Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲstudy of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18): 2786-2792.
[25]	Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲrandomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study[J]. J Clin Oncol,2011,29(3):264-271.
[26]	Schaller G, Bangemann N, Weber J, et al. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase Ⅱstudy of pre-treated metastatic breast cancer [EB/OL]. [2016-02-25].http:/ /meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/717.
[27]	Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19):1783-1791.
[28]	Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006,355(26):2733-2743.
[29]	von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study[J]. J Clin Oncol,2009,27(12):1999-2006.
[30]	Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with erbB2-positive, trastuzumab-refractory metastatic breast cancer[J]. J Clin Oncol,2010,28(7):1124-1130.
[31]	Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study[J]. J Clin Oncol,2012,30(21):2585-2592.
[32]	Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, et al. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy [J]. Cancer Chemother Pharmacol,2010,66(2):269-276.
[33]	Extra JM, Antoine EC, Vincent-Salomon A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study[J].Oncologist,2010,15(8):799-809.
[34]	Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med,2005,353(16):1673-1684.
[35]	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14):1273-1283.
[36]	Baselga J, Perez EA, Pienkowski T, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer[J].Oncologist,2006,11 Suppl 1:4-12.
[37]	Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol,2014,32(33):3744-3752.
[38]	Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer[J].J Clin Oncol,2008,26(8):1216-1222.
[39]	Tolaney SM, Barry WT, Dang CT, et al. A phase Ⅱstudy of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative,HER2-positive breast cancer (BC)[EB/OL]. [2016-02-23]. http:/ /cancerres.aacrjournals.org/content/73/24_Supplement/S1-04.
[40]	Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised,open-label, multicentre,phase 3 trial[J]. Lancet,2012,379(9816):633-640.
[41]	Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial[J]. Lancet Oncol,2013,14(12):1183-1192.
[42]	Lisa AC, Donald AB,David O,et al. Clinical and translational results of CALGB 40601: A neoadjuvant phase Ⅲtrial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer [EB/OL]. [2016-02-20]. http:/ /meetinglibrary. asco. org/content/108409-132.
[43]	Piccart-Gebhart M, Holmes AP,Baselga J,et al. First results from the phase Ⅲ ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D)comparing one year of anti-HER2 therapy with lapatinib alone (L),trastuzumab alone (T), their sequence (T→L), or their combination(T+L) in the adjuvant treatment of HER2-positive early breast cancer(EBC) [EB/OL]. [2016-02-03]. http:/ /meetinglibrary. asco. org/content/128258-144.
[44]	Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol,2012,13(1):25-32.
[45]	Schneeweiss A,Chia S,Hegg R,et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy:an exploratory analysis of the TRYPHAENA study[J]. Breast Cancer Res,2014,16(4): R73.
[46]	Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer[J]. N Engl J Med, 2008, 358(16):1663-1671.
[47]	Sparano JA, Zhao F, Martino S, et al. Long-term follow-up of the E1199 phase Ⅲtrial evaluating the role of taxane and schedule in operable breast cancer [J]. J Clin Oncol,2015,33(21):2353-2360.
[48]	Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial[J].Lancet Oncol,2014,15(7):747-756.
[49]	Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱto Ⅲtriple-negative breast cancer: CALGB 40603 (Alliance)[J]. J Clin Oncol,2015,33(1):13-21.
[50]	von Minckwitz G, Loibl S, Schneeweiss A, et al. Early survival analysis of the randomized phase Ⅱtrial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)[EB/OL]. [2016-02-03]. https:/ /www. sabcs. org/Portals/SABCS/Documents/SABCS-2015-Abstracts.pdf? v=5.
[51]	Sikov WM, Berry DA, Perou CM, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer:Outcomes from CALGB 40603 (Alliance)[EB/OL]. [2016-02-03].http:/ /www.abstracts2view. com/sabcs15/view. php? nu=SABCS15L_1658.
[52]	O'shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase Ⅲstudy of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)[EB/OL]. [2016-02-03]. http:/ /meetinglibrary. asco. org/content/78038-102.
[53]	Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triplenegative breast cancer (CBCSG006): a randomised, open-label,multicentre, phase 3 trial[J]. Lancet Oncol,2015,16(4):436-446.
[54]	Hortobagyi GN, Lipton A, Chew HK, et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial[EB/OL]. [2016-02-03]. http:/ /meetinglibrary.asco.org/content/129791-144.
[55]	Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial[J]. Clin Drug Investig, 2006, 26(6):315-322.
[56]	Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind,multicenter,comparative trial[J]. Cancer,2003,98(8):1735-1744.
[57]	Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term followup of two randomized, placebo-controlled trials[J]. Cancer,2000,88(5):1082-1090.
[58]	Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study[J]. J Clin Oncol,2010,28(35):5132-5139.

Please choose a citation manager

Content to export